Novartis Inks Up to $1.5 Billion Deal to Acquire Gyroscope Therapeutics

Novartis has entered into a definitive agreement to acquire all of the outstanding share capital of the UK-based ocular gene therapy company Gyroscope Therapeutics, bolstering its gene therapy portfolio.

Novartis Inks Up to $1.5 Billion Deal to Acquire Gyroscope Therapeutics
December 23, 2021
Penn Researchers Develop Gene Theraphy That Corrects Dim-light Vision in Dogs

Researchers in the School of Veterinary Medicine and colleagues have developed a gene therapy that restores dim-light vision in dogs with a congenital form of night blindness, offering hope for treating a similar condition in people.

Penn Researchers Develop Gene Theraphy That Corrects Dim-light Vision in Dogs
March 28, 2022
Researchers Describe How Multiple Genes Impact Vision Development and Result in Rare Sight Disorder

An international team of health researchers have, for the first time, described how genetic defects influence the spectrum of vision development and cause problems in developing babies' eyes.

Researchers Describe How Multiple Genes Impact Vision Development and Result in Rare Sight Disorder
April 07, 2022
More